15:53 , Jul 3, 2019 |  BioCentury  |  Emerging Company Profile

Kymera: a systematic approach to protein degradation

With a computational drug discovery platform and a proprietary library of E3 ligases and binders, Kymera believes it can accelerate the discovery and development of protein degraders. Protein degradation is entering the mainstream as a...
20:58 , Jun 13, 2019 |  BC Innovations  |  Finance

Sitting it out: Why some investors are staying out of mega-series A rounds

As series A rounds continue to balloon, some VCs are opting to stay away from super-sized rounds, arguing the large boluses of cash up front can erode financial discipline and constrain exit options, hurting returns....
00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
21:08 , May 23, 2019 |  BC Innovations  |  Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with...
00:21 , May 3, 2019 |  BC Innovations  |  Product Development

With a deal and a debut, targeted oligo delivery gets a boost from ADCs

The marriage of antibody-drug conjugates and oligonucleotides won two votes of confidence last month with a deal between Lilly and Avidity, and the debut of Atlas-backed Dyne Therapeutics. The approach promises delivery of oligos to...
14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
00:24 , Apr 12, 2019 |  BC Innovations  |  Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
17:11 , Apr 5, 2019 |  BC Week In Review  |  Company News

Atlas' build-to-buy Arteaus sells Emgality royalties for $260M

Arteaus sold its royalty rights for Lilly's Emgality galcanezumab-gnlm to Royalty Pharma (New York, N.Y.) for $260 million. Atlas Ventures and OrbiMed Advisors launched Arteaus Therapeutics LLC in October 2011 with $18 million to develop...
20:52 , Apr 3, 2019 |  BC Extra  |  Financial News

Rare muscle disease start-up Dyne raises $50M series A

Founded and incubated by Atlas Venture, newly launched Dyne Therapeutics Inc. (Cambridge, Mass.) announced a $50 million series A round with which it intends to develop therapies that deliver oligonucleotides directly into muscle to treat...